Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and ...
Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal.
Pharmaceuticals announced the first patient has been dosed in the Phase 1/2 study evaluating CRN09682 in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback